Palatin Technologies Inc. (PTN)

[seasonedwell]

But because of these significant differentiating factors of bremelanotide over Addyi, the potential collaboration partners are actually quite enthused about our treatment. Our expectation is that we will be doing collaboration some time after the release of the top line data. In a nice way, as long as what we call a thoughtful evaluation. And in that regard, our expectation is that we will have something between the top line data release and the filing of the NDA with the FDA, which is targeted for mid-calendar year 2017. There is significant interest. There is – yes, Addyi is ahead of us and approved, but obviously there are some questions and some challenges around the product. And frankly, there is – we don’t really see anyone, from a competitive landscape, that close behind us. There is no one through Phase 2. So again, we are comfortable that there is a lot of attention right now and that there will be more attention once we are able to release what we are hoping is the positive Phase 3 trial results.